Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-hr-8160119th CongressWALLET
Premenstrual Dysphoric Disorder Awareness and Research Act of 2026
Sponsored By: Representative Ansari, Yassamin [D-AZ-3]
Introduced
Summary
Expand federal research, awareness, and training on PMDD. This bill would fund expanded NIH research, public education, and clinician training to improve detection and treatment of Premenstrual Dysphoric Disorder (PMDD).
Show full summary
- Patients and families: People with PMDD would see more public education, better screening, and research into new treatments. PMDD affects an estimated 5 to 8 percent of people of reproductive age and can impair work, school, and daily life.
- Health professionals and clinics: Grants would support residency, fellowship, and other training programs for physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians to improve diagnosis and care. The bill authorizes funding across FY2026–FY2031 to support education and workforce training.
- Researchers and data systems: The National Institutes of Health would expand studies on causes, risk factors, diagnosis, and therapies and support clinical trials with diverse populations. The bill also directs surveillance and data collection on PMDD prevalence, economic and workforce impacts, and barriers to diagnosis and treatment.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
More training for PMDD clinicians
This bill would fund grants to accredited schools, hospitals, and residency programs to develop or expand training on PMDD for physicians, nurses, nurse practitioners, physician assistants, pharmacists, and trainees. Eligible entities would need to apply as the Secretary requires, and the Secretary would expand outreach and establish new training opportunities addressing mid-life women's health and related conditions. The bill would also direct HRSA to create and share continuing medical education materials for providers. Grant funding would be authorized for fiscal years 2027 through 2031 and education funding for fiscal years 2026 through 2030.
More research and trials for PMDD
This bill would direct the National Institutes of Health to expand and intensify research on PMDD causes, risk factors, diagnosis, and treatment. It would fund clinical trials to develop improved PMDD treatments and require efforts to include diverse racial, ethnic, and socioeconomic populations. Funding would be authorized as necessary for fiscal years 2027 through 2031.
PMDD data collection and reporting
This bill would require HHS to collect and publish data on PMDD prevalence and incidence, the economic and workforce impact of PMDD, and barriers to diagnosis and treatment. It would also require the Secretary to report to Congress on progress within two years after enactment. Funding would be authorized as necessary for fiscal years 2027 through 2031 to support these activities.
Public campaign on PMDD symptoms
This bill would require HHS to run a public health campaign to raise patient and provider awareness of PMDD symptoms and treatment options. The campaign would aim to reduce stigma around menstrual health and encourage timely medical care, and it would be coordinated through Department programs. Funding would be authorized as necessary for fiscal years 2026 through 2030.
Sponsors & CoSponsors
Sponsor
Ansari, Yassamin [D-AZ-3]
AZ • D
Cosponsors
Rep. Beatty, Joyce [D-OH-3]
OH • D
Sponsored 3/30/2026
Rep. Bell, Wesley [D-MO-1]
MO • D
Sponsored 3/30/2026
Rep. Brownley, Julia [D-CA-26]
CA • D
Sponsored 3/30/2026
Rep. Carter, Troy A. [D-LA-2]
LA • D
Sponsored 3/30/2026
Rep. Clarke, Yvette D. [D-NY-9]
NY • D
Sponsored 3/30/2026
Rep. Conaway, Herbert C. [D-NJ-3]
NJ • D
Sponsored 3/30/2026
Rep. Goldman, Daniel S. [D-NY-10]
NY • D
Sponsored 3/30/2026
Rep. Grijalva, Adelita S. [D-AZ-7]
AZ • D
Sponsored 3/30/2026
Rep. Jackson, Jonathan L. [D-IL-1]
IL • D
Sponsored 3/30/2026
Rep. Johnson, Henry C. "Hank" [D-GA-4]
GA • D
Sponsored 3/30/2026
Rep. Kennedy, Timothy M. [D-NY-26]
NY • D
Sponsored 3/30/2026
Rep. Krishnamoorthi, Raja [D-IL-8]
IL • D
Sponsored 3/30/2026
Rep. McGarvey, Morgan [D-KY-3]
KY • D
Sponsored 3/30/2026
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 3/30/2026
Rep. Pressley, Ayanna [D-MA-7]
MA • D
Sponsored 3/30/2026
Rep. Ross, Deborah K. [D-NC-2]
NC • D
Sponsored 3/30/2026
Rep. Thanedar, Shri [D-MI-13]
MI • D
Sponsored 3/30/2026
Rep. Tlaib, Rashida [D-MI-12]
MI • D
Sponsored 3/30/2026
Rep. Tonko, Paul [D-NY-20]
NY • D
Sponsored 3/30/2026
Rep. Trahan, Lori [D-MA-3]
MA • D
Sponsored 3/30/2026
Rep. Velázquez, Nydia M. [D-NY-7]
NY • D
Sponsored 3/30/2026
Rep. Williams, Nikema [D-GA-5]
GA • D
Sponsored 3/30/2026
Rep. Wilson, Frederica S. [D-FL-24]
FL • D
Sponsored 3/30/2026
Rep. Fletcher, Lizzie [D-TX-7]
TX • D
Sponsored 4/2/2026
Rep. Bonamici, Suzanne [D-OR-1]
OR • D
Sponsored 4/2/2026
Rep. McClain Delaney, April [D-MD-6]
MD • D
Sponsored 4/13/2026
Rep. Underwood, Lauren [D-IL-14]
IL • D
Sponsored 5/7/2026
Rep. Jayapal, Pramila [D-WA-7]
WA • D
Sponsored 6/3/2026
Rep. McBride, Sarah [D-DE-At Large]
DE • D
Sponsored 6/24/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov